• Foscarnet prophylaxis improved engraftment and survival in cord blood transplant patients

    Six-month overall survival was 96% in the treated group compared to 72% in the untreated group.

  • Latent HHV-6B infection of astrocytes may increase the risk of depression by activating the HPA axis

    Japanese investigators show that a protein expressed by latent HHV-6B in astrocytes, results in an influx of extra-cellular calcium, triggering the onset of depression.

  • Mothers with iciHHV6 have an increased risk of spontaneous abortion

    27.6% of Japanese mothers with iciHHV6 had a spontaneous abortion compared to 14.8% of controls. iciHHV6 mothers were also 6.4X more likely to have two or more spontaneous abortions.

  • Significantly worse outcomes in critically ill hematology patients associated with HHV-6 infection.

    Two reports associate detectable HHV-6 DNA in body fluids with increased risk of mortality in patients being treated for hematologic malignancies.

Newsletter | About Us | Contact Us | Donate | Repository

HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant Navigation
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications
  • Home
  • About
    • Scientific Office
    • Scientific Advisory Board
    • Executive Director & Staff
    • Board of Directors
    • Contact Us
    • Donate
  • Patients
    • What Is HHV-6?
    • HHV-6A/B Testing
    • HHV-6 Treatment
    • Patient FAQ
    • Conditions Associated with HHV-6
    • HHV-6 & Immune Suppression
    • Immune Stimulants
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
  • Research
    • Latest HHV-6 Research
    • Grants
    • Repository
      • Cart
      • Checkout
    • HHV-6A/B Testing
    • List of Genes & Proteins
    • Lab Protocols
    • Pictorial Atlas of HHV-6
    • HHV-6 Antivirals
    • Researcher FAQ
    • Newsletter
  • Clinicians
    • HHV-6A/B Testing
    • HHV-6 Treatment
      • HHV-6 Antivirals
      • Immune Stimulants
    • Alternative Treatments
      • Antiviral use in transplant patients with HHV-6 encephalitis
      • More about foscarnet, ganciclovir and cidovofir
    • HHV-6 & Immune Suppression
    • Chromosomally Integrated HHV-6 (ciHHV-6)
    • CIHHV-6 Testing
    • 10 Surprising Facts about CIHHV-6
  • Conditions
    • Associated Conditions A-H
      • Amnesia
      • Cancer
      • Chromosomally Integrated HHV-6 (ciHHV-6)
      • Chronic Fatigue Syndrome
      • Cognitive Dysfunction
      • Colitis/Diarrhea
      • Drug Hypersensitivity
      • Encephalitis
      • Endocrine Disorders
      • Endothelial Cell Dysfunction
      • Epilepsy
      • Heart Disease
      • HIV/AIDS Progression
    • Associated Conditions I-Z
      • Immune Suppression
      • Kidney Disease
      • Liver Disease
      • Lung Disease
      • Mononucleosis/Lymphadenopathy
      • Multiple Sclerosis
      • Neurological Conditions
      • Organ-Specific Diseases
      • Rash/Roseola
      • Transplant Complications

Latest CNS Disease Articles

View Post

The presence of HHV-6 DNA in nasal swabs correlates with neurological symptoms in patients with severe COVID-19

40% of the patients with HHV-6 DNA had CNS symptoms, compared to 14.3% of the HHV-6 negative patients.

View Post

A relationship between human endogenous retroviruses and HHV-6A/B in multiple sclerosis patients

Significant positive correlations were found between HERV family proteins and antibodies to HHV-6A/B but not antibodies to EBV

View Post

CMV infection may diminish the risk of developing MS

Studies conducted on serum obtained before development of MS indicate possible protective role

View Post

Detection of HHV-6 miRNA in Multiple Sclerosis patients

HHV-6 miRNAs and antibodies were identified and significantly correlated with each other in serum and CSF of MS patients

View Post

Abnormal cytokine levels in children with epilepsy suggest link to inflammation

Unique pathways and significantly elevated cytokines were associated with a small cohort of pediatric seizure patients.

View Post

Imunocompromised patients with HHV-6 encephalitis have a ratio of CSF/blood viral load >1, whereas children with encephalitis due to primary infection have ratios of <1

Immunocompetent cases are typically children experiencing primary infection with high viral loads in the blood; cases in the immunocompromised typically involve reactivation in the brain tissue, with lower viral loads in the periphery

View Post

HHV-6 encephalitis can occur in CAR T-cell therapy and biologic immunotherapy

As with chemotherapy, immunotherapies for cancer can lead to HHV-6 encephalitis

View Post

Large serologic study incriminates both EBV and HHV-6A as triggers of multiple sclerosis

HHV-6A infection at any age, and EBV infection after age 20, were found to be significant risk factors

View Post

HHV-6 accounted for 5% of all herpetic viral encephalitis in immunocompetent Mexican patients

Psychiatric disorders were the most common prodomal symptom (58%) and this was significantly different from patients with non-herpesvirus encephalitis.

View Post

A review of the role of HHV-6A in multiple sclerosis and HHV-6B in epilepsy

Neuroscientists at Karolinska Institute in Sweden summarized the growing literature linking HHV-6A/B to both illnesses.

View Post

HHV-6 DNA found in spinal fluid of 8% of patients with aseptic meningitis

Multiplex testing for the causative agents of aseptic meningitis in Saudi Arabia identifies possible etiologic role for HHV-6

View Post

No HHV-6 DNA found in the spinal fluid of immunocompetent adults evaluated for limbic encephalitis

While HHV-6B is well known to cause limbic encephalitis in transplant patients, it does not appear to play a role in other forms of limbic encephalitis.

View Post

Study of fresh brain tissue confirms a role for HHV-6 in mesial temporal sclerosis

NINDS investigators studied fresh resected brain tissue and found 29 of 54 positive for HHV-6 DNA. Previous studies using formalin fixed and paraffin embedded samples have yielded much lower rates of positivity.

View Post

Alcoholism and HHV-6B infection may interact to produce microglial activation, migration in the substantia nigra

Possible synergy between chronic alcohol use and HHV-6B infection of substantia nigra in producing microglial activation

View Post

HHV-6A and the suppression of miR155 in Alzheimer’s pathology

Dysregulation of the microRNA miR155 is associated with pathophysiological progression of Alzheimer’s disease. HHV-6A has been shown to suppress miR155.

  • Page 2 of 5
  • ←
  • 1
  • 2
  • 3
  • ...
  • 5
  • →

Clinical News

  • Alzheimer’s Disease
  • Animal Models
  • Autoimmune Disease
  • Cancer
  • iciHHV-6
  • CNS Disease
  • COVID-19 / HHV-6 Reactivation
  • Drug Hypersensitivity
  • Encephalitis & Encephalopathy
  • Endocrine Conditions
  • Epilepsy and Seizures
  • Gastrointestinal
  • Genes
  • Heart Disease
  • Hematological Disorders
  • HIV/AIDS Progression
  • Immunity & Immunotherapy
  • Infertility & Miscarriage
  • Kidney Disease
  • Liver Disease
  • Lung Disease
  • Lymphadenopathy & Fever
  • ME/CFS
  • Multiple Sclerosis
  • Rash & Roseola
  • Transplant Complications
  • Treatments – Adoptive T cell
  • Treatments – Alternative
  • Treatments – Antiviral
  • Treatments – Immune Stimulant

Scientific News

  • Latest Scientific News

About HHV-6

  • What Is HHV-6?
  • What is Inherited Chromosomally Integrated HHV-6
  • HHV-6 Repository of Reagents
  • HHV-6A/B Testing
  • HHV-6 Treatment

SUBSCRIBE TO OUR NEWSLETTER

ABOUT THE HHV-6 FOUNDATION

The HHV-6 Foundation in a non-profit entity founded to encourage scientific exchange between investigators and to provide pilot grants for promising scientific and clinical research on the under- appreciated viruses HHV-6A and HHV-6B.

The Foundation sponsors international conferences and supports scientists and clinicians seeking to clarify the role of the two HHV-6 viruses in disease. Since HHV-6A and HHV-6B can smolder in the brain and other organs without circulating in the peripheral blood or plasma, identifying chronic infection is a challenge.

Read More

HHV-6 Foundation | 1482 East Valley Road, Suite 619 | Santa Barbara, CA, 93108 | Toll Free: (888) 530-6726


Copyright ©2004-2022 HHV-6 FOUNDATION


WEB DESIGN AND DEVELOPMENT BY INSTYLE TECHNOLOGIES
  • Home
  • About
  • Conditions
  • Clinicians
  • Testing
  • Research
  • Repository
  • Patients
  • Treatment
  • News & Blog
  • Donate
  • Contact Us
  • Cart
  • Checkout
  • Privacy Policy
  • Terms of Use